Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Stability01:53

RNA Stability

35.6K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
35.6K
RNA Structure01:23

RNA Structure

78.8K
Overview
The basic structure of RNA consists of a five-carbon sugar and one of four nitrogenous bases. Although most RNA is single-stranded, it can form complex secondary and tertiary structures. Such structures play essential roles in the regulation of transcription and translation.
Different Types of RNA Have the Same Basic Structure
There are three main types of ribonucleic acid (RNA): messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). All three RNA types consist of a...
78.8K
RNA Splicing01:32

RNA Splicing

60.4K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.4K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
Types of RNA01:23

Types of RNA

72.6K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
72.6K
Transfer RNA Synthesis02:36

Transfer RNA Synthesis

13.2K
One of the unique features of tRNA is the presence of modified bases. In some tRNAs, modified bases account for nearly 20% of the total bases in the molecule. Altogether, these unusual bases protect the tRNA from enzymatic degradation by RNases.
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
13.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metformin improves RAN protein pathology, alternative splicing, and behavioral phenotypes in SCA8 mice.

Life science alliance·2026
Same author

Modified Polycyclic Compounds Rescue Mis-splicing in Myotonic Dystrophy Type 1 Disease Models.

ACS chemical biology·2026
Same author

Identification of enzymatically modified isoquercitrin as a therapeutic lead for myotonic dystrophy type 1.

NAR molecular medicine·2026
Same author

Inosine misincorporation into mRNA triggers the integrated stress response and activates an innate immune gene expression signature.

bioRxiv : the preprint server for biology·2026
Same author

Counterions influence the isothermal self-assembly of DNA nanostructures.

Science advances·2025
Same author

Dysregulation of alternative splicing is a transcriptomic feature of patient-derived fibroblasts from CAG repeat expansion spinocerebellar ataxias.

Human molecular genetics·2024

Related Experiment Video

Updated: Jan 20, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.9K

Mitigating RNA Toxicity in Myotonic Dystrophy using Small Molecules.

Kaalak Reddy1, Jana R Jenquin2, John D Cleary3

  • 1The RNA Institute, University at Albany-SUNY, Albany, NY 12222, USA. kreddy2@albany.edu.

International Journal of Molecular Sciences
|August 21, 2019
PubMed
Summary
This summary is machine-generated.

This review explores small molecule therapeutics for myotonic dystrophy (DM) types 1 and 2. It examines strategies targeting DNA, RNA, and proteins involved in DM pathogenesis and progression.

Keywords:
myotonic dystrophysmall moleculestherapies

More Related Videos

Nanomanipulation of Single RNA Molecules by Optical Tweezers
06:59

Nanomanipulation of Single RNA Molecules by Optical Tweezers

Published on: August 20, 2014

15.4K
A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
05:54

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy

Published on: December 29, 2017

10.5K

Related Experiment Videos

Last Updated: Jan 20, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.9K
Nanomanipulation of Single RNA Molecules by Optical Tweezers
06:59

Nanomanipulation of Single RNA Molecules by Optical Tweezers

Published on: August 20, 2014

15.4K
A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
05:54

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy

Published on: December 29, 2017

10.5K

Area of Science:

  • Biomedical Research
  • Molecular Biology
  • Drug Discovery

Background:

  • Myotonic dystrophy (DM) is a progressive multisystem disorder.
  • DM types 1 and 2 (DM1, DM2) share common features but differ in genetic basis.
  • Current therapeutic options for DM are limited.

Purpose of the Study:

  • To review the development of small molecule therapeutics for DM.
  • To assess the potential of targeting DNA, RNA, and proteins in DM treatment.
  • To provide an overview of current therapeutic strategies for DM1 and DM2.

Main Methods:

  • Literature review of small molecule approaches for DM.
  • Analysis of therapeutic strategies targeting molecular mechanisms of DM.
  • Synthesis of information on DM pathogenesis and small molecule interventions.

Main Results:

  • Various small molecule strategies are under investigation for DM.
  • Approaches target key molecular players including DNA, RNA, and proteins.
  • The review consolidates current research on potential DM therapeutics.

Conclusions:

  • Small molecules represent a promising therapeutic avenue for DM.
  • Targeting specific molecular defects in DM1 and DM2 is feasible.
  • Further research and development are crucial for clinical translation.